Other Events ·
Gain Therapeutics, Inc. announced on June 29, 2026, that the U.S. Food and Drug Administration (FDA) authorized its…
GANXGain Therapeutics, Inc.
Gain Therapeutics, Inc. announced on June 29, 2026, that the U.S. Food and Drug Administration (FDA) authorized its Investigational New Drug application for GT-02287. This authorization allows the company to initiate Phase 2 clinical development of GT-02287 for Parkinson's disease in the United States, Australia, and Europe. The company anticipates the initiation of the Phase 2a study of oral GT-02287 in participants with early Parkinson's disease during the third quarter of 2026. Gain Therapeutics, Inc. is a biotechnology company focused on the development of therapeutic candidates for neurological and neurological-related diseases.